Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), COMPASS Pathways (CMPS) and Pfizer (PFE)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Qiagen (QGEN), COMPASS Pathways (CMPS) and Pfizer (PFE) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Qiagen (QGEN)
Deutsche Bank analyst Jan Koch maintained a Buy rating on Qiagen today. The company’s shares closed last Wednesday at $41.95.
Koch has an average return of
According to TipRanks.com, Koch is ranked #11992 out of 12430 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $41.98 average price target, which is a -0.8% downside from current levels. In a report released today, Jefferies also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
COMPASS Pathways (CMPS)
In a report released today, Judah Frommer from Morgan Stanley maintained a Buy rating on COMPASS Pathways, with a price target of $18.00. The company’s shares closed last Wednesday at $13.58.
According to TipRanks.com, Frommer is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for COMPASS Pathways with a $24.14 average price target, representing a 108.1% upside. In a report issued on July 23, TipRanks – Google also upgraded the stock to Buy with a $13.50 price target.
Pfizer (PFE)
In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer. The company’s shares closed last Wednesday at $25.81.
Kraus has an average return of
According to TipRanks.com, Kraus is ranked #2687 out of 12430 analysts.
Currently, the analyst consensus on Pfizer is a Hold with an average price target of $28.18, a 10.5% upside from current levels. In a report issued on July 22, BMO Capital also maintained a Buy rating on the stock with a $30.00 price target.
Read More on QGEN:
